Security
Zevra Therapeutics, Inc. Common Stock · ZVRA
ZVRANASDAQCommon stockCurrentCIK 1434647Updated Oct 14, 2026
Name history
KEMPHARM, INC · through Feb 24, 2023KEMPHARM INC · through Jun 30, 2011
ZVRA price & chart
Loading TradingView…
NASDAQ:ZVRA on TradingView ↗About the company
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values - patient centricity, integrity, accountability, innovation, and courage - which guide its efforts to deliver long-term value.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 270,116,000Source | 191,551,000Source | 302,712,000Source | 256,277,000Source | 144,408,000Source | 278,579,000Source | 172,708,000Source | 151,283,000Source | 284,731,000Source | 178,127,000Source | 172,327,000Source | 115,529,000Source |
| Property, Plant and Equipment, NetUSD | 488,000Source | 607,000Source | 641,000Source | 599,000Source | 678,000Source | 430,000Source | 422,000Source | 695,000Source | 489,000Source | 356,000Source | 736,000Source | 794,000Source |
| GoodwillUSD | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 6,737,000Source | 70,608,000Source | 5,789,000Source | 7,053,000Source | 66,154,000Source | 6,105,000Source | 67,377,000Source | 67,699,000Source | 6,421,000Source | 68,993,000Source | 69,227,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 54,439,000Source | 54,039,000Source | 145,321,000Source | 47,712,000Source | 39,260,000Source | 95,595,000Source | 37,340,000Source | 42,849,000Source | 62,406,000Source | 33,785,000Source | 43,049,000Source | 65,466,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | 10,176,000Source | 16,119,000Source | 7,185,000Source |
| Inventory, NetUSD | 1,367,000Source | — | 2,449,000Source | 1,108,000Source | — | 2,310,000Source | 2,559,000Source | — | 1,740,000Source | 1,970,000Source | 9,841,000Source | — |
| Assets, CurrentUSD | 225,115,000Source | 99,442,000Source | 251,302,000Source | 226,337,000Source | 60,891,000Source | 229,968,000Source | 81,573,000Source | 62,890,000Source | 223,007,000Source | 86,027,000Source | 86,938,000Source | 93,023,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,398,000Source | 2,276,000Source | 4,794,000Source | 4,352,000Source | 2,686,000Source | 4,944,000Source | 3,766,000Source | 1,868,000Source | 6,998,000Source | 4,052,000Source | 1,824,000Source | 1,877,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,337,000Source | 820,000Source | 1,667,000Source | 1,496,000Source | 911,000Source | 1,087,000Source | 1,636,000Source | 1,086,000Source | 1,212,000Source | 657,000Source | 790,000Source | 988,000Source |
| Other Assets, NoncurrentUSD | 153,000Source | 512,000Source | 3,000Source | 220,000Source | 875,000Source | 143,000Source | 293,000Source | 1,786,000Source | 143,000Source | 384,000Source | 94,000Source | 53,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 136,951,000Source | 121,781,000Source | 85,060,000Source | 139,047,000Source | 111,930,000Source | 72,775,000Source | 131,685,000Source | 102,465,000Source | 130,074,000Source | 138,461,000Source | 110,463,000Source | 29,722,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | — | — | 0Source | — | — | 0Source |
| Common Stock, Value, IssuedUSD | — | 5,000Source | — | — | 4,000Source | — | 5,000Source | 4,000Source | — | 5,000Source | 4,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -434,225,000Source | -469,550,000Source | -375,418,000Source | -433,681,000Source | -436,325,000Source | -384,170,000Source | -508,388,000Source | -416,400,000Source | -422,060,000Source | -505,289,000Source | -399,778,000Source | -308,572,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,416,000Source | -115,000Source | -2,217,000Source | -2,428,000Source | 421,000Source | -1,797,000Source | -82,000Source | 141,000Source | -764,000Source | 631,000Source | -43,000Source | 113,000Source |
| Stockholders' Equity Attributable to ParentUSD | 133,165,000Source | 69,770,000Source | 217,652,000Source | 117,230,000Source | 32,478,000Source | 205,804,000Source | 41,023,000Source | 48,818,000Source | 154,657,000Source | 39,666,000Source | 61,864,000Source | 85,807,000Source |
| Additional Paid in Capital, Common StockUSD | 580,783,000Source | 550,413,000Source | 606,264,000Source | 564,316,000Source | 479,361,000Source | 602,748,000Source | 560,471,000Source | 476,056,000Source | 588,458,000Source | 555,302,000Source | 472,664,000Source | 401,799,000Source |
| Liabilities and EquityUSD | 270,116,000Source | 191,551,000Source | 302,712,000Source | 256,277,000Source | 144,408,000Source | 278,579,000Source | 172,708,000Source | 151,283,000Source | 284,731,000Source | 178,127,000Source | 172,327,000Source | 115,529,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 26,112,000Source | 34,481,000Source | 48,632,000Source | 28,832,000Source | 30,449,000Source | 47,028,000Source | 26,976,000Source | 29,909,000Source | 39,277,000Source | 34,065,000Source | 73,720,000Source | 11,726,000Source |
| Operating Lease, Liability, CurrentUSD | 441,000Source | 540,000Source | 626,000Source | 525,000Source | 596,000Source | 406,000Source | 589,000Source | 583,000Source | 419,000Source | 420,000Source | 543,000Source | 480,000Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | 2,478,000Source | 13,075,000Source | 13,987,000Source | 3,611,000Source |
| Operating Lease, Liability, NoncurrentUSD | 966,000Source | 483,000Source | 870,000Source | 1,059,000Source | 544,000Source | 741,000Source | 1,158,000Source | 705,000Source | 859,000Source | 372,000Source | 456,000Source | 843,000Source |
| Other Liabilities, NoncurrentUSD | 3,995,000Source | 5,521,000Source | 2,087,000Source | 3,316,000Source | 6,638,000Source | 1,859,000Source | 4,876,000Source | 8,537,000Source | 1,713,000Source | 4,630,000Source | 7,458,000Source | 25,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 67,700,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 173,000Source | 1,103,000Source | 164,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 61,310,000Source | 58,904,000Source | 0Source | 60,692,000Source | 58,328,000Source | 0Source | 60,090,000Source | — | 61,928,000Source | 59,504,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 368,000Source | 1,649,000Source | 4,054,000Source | 6,389,000Source | 1,006,000Source | 944,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,105,000Source | 3,115,000Source | 12,634,000Source | 14,906,000Source | 5,954,000Source | 4,294,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 185,000Source | 205,000Source | 1,305,000Source | 8,874,000Source | -206,000Source | -147,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -9,846,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 6,142,000Source | -8,222,000Source | -1,598,000Source | -69,665,000Source | -33,535,000Source | -18,717,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 0Source | 30,401,000Source | 14,090,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 79,618,000Source | 10,542,000Source | 18,127,000Source | -22,161,000Source | -17,390,000Source | -36,719,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 35,000Source | 99,000Source | 835,000Source | 0Source | 296,000Source | 93,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,447,000Source | 4,723,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -52,804,000Source | 1,607,000Source | 12,064,000Source | 82,108,000Source | 28,464,000Source | 8,352,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 33,189,000Source | 3,555,000Source | 28,621,000Source | -9,264,000Source | -22,417,000Source | -46,880,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,370,000Source | 1,306,000Source | 5,329,000Source | 5,262,000Source | 456,000Source | 321,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,771,000Source | 6,137,000Source | 2,969,000Source | 2,464,000Source | 3,105,000Source | 3,115,000Source | 12,634,000Source | 14,906,000Source | 5,954,000Source | 4,294,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Amortization of Intangible AssetsUSD | — | — | 315,000Source | 1,545,000Source | 316,000Source | 1,616,000Source | 316,000Source | 1,615,000Source | 3,862,000Source | 6,235,000Source | 800,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 67,700,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 200,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 1,403,000Source | -213,000Source | -1,548,000Source | -219,000Source | 198,000Source | 91,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | 0Source | 0Source | 0Source | 148,325,000Source | 43,314,000Source | 0Source | 148,325,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | 0Source | 0Source | -2,756,000Source | 0Source | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 15,343,000Source |
| GoodwillUSD | — | — | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | 4,701,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 0Source | — | 58,710,000Source | 43,300,000Source | 0Source | 58,710,000Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | -433,000Source | 0Source | 4,042,000Source | 2,199,000Source | 6,914,000Source | 1,182,000Source | 3,449,000Source | 15,371,000Source | 0Source | -786,000Source |
| InterestExpenseNonoperatingUSD | — | — | 2,051,000Source | 2,312,000Source | 0Source | 2,009,000Source | 1,711,000Source | 1,969,000Source | 7,977,000Source | 7,351,000Source | — | — |
| Inventory Write-downUSD | — | — | 0Source | 2,000,000Source | 0Source | 11,700,000Source | 485,000Source | 0Source | 11,681,000Source | 5,746,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -544,000Source | -33,225,000Source | 8,752,000Source | 74,707,000Source | 37,890,000Source | -3,099,000Source | 83,229,000Source | -105,511,000Source | -46,049,000Source | -41,543,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -544,000Source | -33,225,000Source | 8,393,000Source | 67,909,000Source | 36,317,000Source | -3,099,000Source | 77,585,000Source | -105,511,000Source | -46,049,000Source | -41,543,000Source |
| Nonoperating Income (Expense)USD | — | — | -5,120,000Source | -5,919,000Source | -3,983,000Source | 147,945,000Source | -7,342,000Source | 3,445,000Source | 149,621,000Source | -3,137,000Source | 3,555,000Source | 176,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 0Source | 2,091,000Source | — | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 45,814,000Source | 22,536,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 64,516,000Source | 6,106,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 1,979,000Source | 3,182,000Source | 1,684,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 26,063,000Source | 3,695,000Source | 39,663,000Source | 25,881,000Source | 36,220,000Source | 20,401,000Source | 106,470,000Source | 23,612,000Source | 27,461,000Source | 10,458,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | -3,000,000,000Source | 149,000Source | 18,000,000,000Source | 600,000Source | -577,000Source |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Unrealized Gain (Loss) on Derivatives | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 16,935,000Source | 16,208,000Source | 16,559,000Source | 20,782,000Source | 20,783,000Source | 19,545,000Source | 77,616,000Source | 54,868,000Source | 34,314,000Source | — |
| Operating Income (Loss)USD | — | — | 4,143,000Source | -27,306,000Source | 16,777,000Source | -71,039,000Source | 52,146,000Source | -5,362,000Source | -62,943,000Source | -87,003,000Source | -49,604,000Source | -42,505,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -977,000Source | -33,225,000Source | 12,794,000Source | 76,906,000Source | 44,804,000Source | -1,917,000Source | 86,678,000Source | -90,140,000Source | -46,049,000Source | -42,329,000Source |
| Income Tax Expense (Benefit)USD | — | — | -433,000Source | 0Source | 4,042,000Source | 2,199,000Source | 6,914,000Source | 1,182,000Source | 3,449,000Source | 15,371,000Source | 0Source | -786,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -544,000Source | -33,225,000Source | 8,752,000Source | 74,707,000Source | 37,890,000Source | -3,099,000Source | 83,229,000Source | -105,511,000Source | -46,049,000Source | -41,543,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.01Source | -0.69Source | 0.14Source | 1.24Source | 0.62Source | -0.06Source | 1.4Source | -2.28Source | -1.3Source | -1.2Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.01Source | -0.69Source | 0.14Source | 1.21Source | 0.6Source | -0.06Source | 1.35Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 55,951,572Source | 47,808,817Source | 59,155,970Source | 54,780,938Source | 58,405,955Source | 54,095,543Source | 55,311,308Source | 46,251,239Source | 35,452,460Source | 34,488,800Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 55,951,572Source | 47,808,817Source | 61,336,617Source | 56,324,903Source | 60,230,490Source | 54,095,543Source | 57,262,715Source | — | — | — |
| Interest Expense (non-operating)USD | — | — | 2,051,000Source | 2,312,000Source | 0Source | 2,009,000Source | 1,711,000Source | 1,969,000Source | 7,977,000Source | 7,351,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 315,000Source | 1,545,000Source | 316,000Source | 1,616,000Source | 316,000Source | 1,615,000Source | 3,862,000Source | 6,235,000Source | 800,000Source | — |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | 1,238,000Source | 2,303,000Source | 1,525,000Source | 12,379,000Source | 1,897,000Source | 1,345,000Source | 16,482,000Source | 7,417,000Source | — | — |
| Costs and ExpensesUSD | — | — | 20,367,000Source | 27,153,000Source | 21,045,000Source | 24,215,000Source | 25,175,000Source | 22,803,000Source | 90,359,000Source | 96,963,000Source | 77,065,000Source | 52,963,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 13,295,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 1,403,000Source | -213,000Source | -1,548,000Source | -219,000Source | 198,000Source | 91,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 15,343,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 27,140,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,501,000Source | 335,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -544,000Source | -33,225,000Source | 8,393,000Source | 67,909,000Source | 36,317,000Source | -3,099,000Source | 77,585,000Source | -105,511,000Source | -46,049,000Source | -41,543,000Source |
| Nonoperating Income (Expense)USD | — | — | -5,120,000Source | -5,919,000Source | -3,983,000Source | 147,945,000Source | -7,342,000Source | 3,445,000Source | 149,621,000Source | -3,137,000Source | 3,555,000Source | 176,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | 0Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 26,063,000Source | 3,695,000Source | 39,663,000Source | 25,881,000Source | 36,220,000Source | 20,401,000Source | 106,470,000Source | 23,612,000Source | 27,461,000Source | 10,458,000Source |
Filing attachments
zvra-20260316xex991.htm · 8-K · 2026-03-16
EX-99.1 2 zvra-20260316xex991.htm EX-99.1 Document Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million Companies Resolve Lawsuit in Delaware BOSTON, Mass., Mar. 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra’s serdexmethylpheni…
Read attachment ↗zvra-20251202xex991.htm · 8-K · 2025-12-02
EX-99.1 2 zvra-20251202xex991.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD Celebration, FL - December 2, 2025 - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company’s Board of Directors (Board). The…
Read attachment ↗d78999dex991.htm · 8-K · 2025-11-20
EX-99.1 2 d78999dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Zevra Therapeutics, Inc. Announces CFO Transition Celebration, FL - November 20, 2025 - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, …
Read attachment ↗zvra-20251105xex991.htm · 8-K · 2025-11-05
EX-99.1 2 zvra-20251105xex991.htm EX-99.1 Document Exhibit 99.1 Zevra Reports Third Quarter 2025 Financial Results and Corporate Update 2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., November 5, 2025 -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapie…
Read attachment ↗zvra-20250812xex991.htm · 8-K · 2025-08-12
EX-99.1 2 zvra-20250812xex991.htm EX-99.1 Document Exhibit 99.1 Zevra Reports Second Quarter 2025 Financial Results and Corporate Update Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the…
Read attachment ↗d938703dex991.htm · 8-K · 2025-04-07
EX-99.1 2 d938703dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million Celebration, FL - Apr. 7, 2025 - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million. “We h…
Read attachment ↗